Literature DB >> 9845425

Evaluation and interpretation of iron in the liver.

B Turlin1, Y Deugnier.   

Abstract

Faced with hepatic siderosis, the pathologist must (1) determine the parenchymal, mesenchymal, or mixed type of iron overload; (2) quantify liver iron by either histology or biochemistry; (3) seek for associated iron-related lesions, especially sideronecrosis, fibrosis, and iron-free-foci; and (4) assess any other liver damage. The discovery of the HFE gene has modified the management of hemochromatosis. Because homozygosity for the C282Y mutation is diagnostic of the condition regardless of the liver iron concentration-to-age ratio, indication for liver biopsy in C282Y homozygotes is restricted to the assessment of prognostic lesions, such as fibrosis and iron-free-foci. In patients with a phenotype compatible with hemochromatosis but nonhomozygous for the C282Y mutation, liver biopsy remains mandatory to assess nonhemochromatosis causes of iron overload (rare hereditary defects of iron metabolism and transport and iron overload secondary to polymetabolic syndrome, to porphyria cutanea tarda, or to cirrhosis). The evaluation of iron distribution within liver cells and throughout lobules and the assessment of associated lesions are the most important features that allow for correct classification of nonhemochromatosis iron-overload syndromes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845425

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  9 in total

Review 1.  Hepcidin: what every gastroenterologist should know.

Authors:  A P Walker; J Partridge; S K Srai; J S Dooley
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

2.  Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis.

Authors:  Deepak Amarapurkar; Anjali Amarapurkar
Journal:  J Clin Exp Hepatol       Date:  2015-10-23

Review 3.  Pathology of Hepatic Iron Overload.

Authors:  Marcela A Salomao
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

4.  Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.

Authors:  Mustafa R Bashir; Tanya Wolfson; Anthony C Gamst; Kathryn J Fowler; Michael Ohliger; Shetal N Shah; Adina Alazraki; Andrew T Trout; Cynthia Behling; Daniela S Allende; Rohit Loomba; Arun Sanyal; Jeffrey Schwimmer; Joel E Lavine; Wei Shen; James Tonascia; Mark L Van Natta; Adrija Mamidipalli; Jonathan Hooker; Kris V Kowdley; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2018-10-14       Impact factor: 4.813

5.  Integrated quantitative susceptibility and R2 * mapping for evaluation of liver fibrosis: An ex vivo feasibility study.

Authors:  Ramin Jafari; Stefanie J Hectors; Anne K Koehne de González; Pascal Spincemaille; Martin R Prince; Gary M Brittenham; Yi Wang
Journal:  NMR Biomed       Date:  2020-09-22       Impact factor: 4.044

Review 6.  Pathology of hepatic iron overload.

Authors:  Yves Deugnier; Bruno Turlin
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

7.  Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C.

Authors:  Hironori Mitsuyoshi; Kohichiroh Yasui; Kanji Yamaguchi; Masahito Minami; Takeshi Okanoue; Yoshito Itoh
Journal:  Int J Hepatol       Date:  2013-04-04

8.  The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients.

Authors:  Glenn S Gerhard; Ravi Chokshi; Christopher D Still; Peter Benotti; G Craig Wood; Mollie Freedman-Weiss; Cody Rider; Anthony T Petrick
Journal:  Patient Saf Surg       Date:  2011-01-10

9.  The role of MR imaging in detection of hepatic iron overload in patients with cirrhosis of different origins.

Authors:  Edyta Szurowska; Katarzyna Sikorska; E Izycka-Swieszewska; Tomasz Nowicki; Tomasz Romanowski; Krzysztof P Bielawski; Michał Studniarek
Journal:  BMC Gastroenterol       Date:  2010-01-27       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.